Acute Myeloid Leukemia Pathophysiology

NewsGuard 100/100 Score

Cancer arises when the genes and DNA within the cell are damaged. In a normal cell this DNA guides the actions, functions, growth, maturity, division and ultimately death of the cell.

Cancer is usually caused if there is an alteration or mutation of DNA. The changes in the DNA can cause normal bone marrow cells to become leukemia cells.

Oncogenes and tumor suppressor genes

There is presence of normal genes that help cells to grow. These are called Oncogenes. Yet other types of genes that slow growth of cells are called tumor suppressor genes. These tumor suppressor genes slow down cell growth and division or cause them to die at appropriate times. Cancer occurs when this balance between Oncogenes and tumor suppressor genes is altered.

Types of DNA error

Common errors seen in DNA are called mutations. Translocations are the most common type of DNA change that form the basis of leukemia. A translocation means that DNA from one chromosome breaks off and becomes attached to another chromosome. This break off at a chromosome can turn on oncogenes or turn off tumor suppressor genes leading to cancers.


The malignant cells in AML are the myeloblasts. The myeloblast is an immature precursor of myeloid white blood cells. This myeloblast matures into a mature white blood cell.

In AML a single myeloblast may undergo the genetic change that fixes the cell in its immature state and prevents maturation and differentiation.

In the majority of cases this mutation alone is incapable of causing leukemia. When this mutation and arrest in the immature stage is combined with other mutations which disrupt genes controlling proliferation (Oncogenes) the condition may give rise to AML.

Leukemic transformation can occur at a number of different steps along the differentiation pathway of the myeloblasts. The classification of AML follows the stage at which the maturation of the myeloblasts is arrested.

Cytogenetic abnormalities

Patients with AML in addition may have specific cytogenetic abnormalities. These abnormalities may predict the prognostic significance of the type of AML as well.

The abnormalities or mutations code for an abnormal gene that in turn makes abnormal fusion proteins. These abnormal proteins are usually transcription factors that may finally lead to arrest of differentiation.

For example, in acute promyelocytic leukemia (APL) a translocation t(15;17) produces a PML-RARα fusion protein. This binds to the retinoic acid receptor element in the promoters of several myeloid-specific genes and inhibits myeloid differentiation.

Further Reading

Last Updated: Jun 10, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, June 10). Acute Myeloid Leukemia Pathophysiology. News-Medical. Retrieved on May 22, 2024 from

  • MLA

    Mandal, Ananya. "Acute Myeloid Leukemia Pathophysiology". News-Medical. 22 May 2024. <>.

  • Chicago

    Mandal, Ananya. "Acute Myeloid Leukemia Pathophysiology". News-Medical. (accessed May 22, 2024).

  • Harvard

    Mandal, Ananya. 2023. Acute Myeloid Leukemia Pathophysiology. News-Medical, viewed 22 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells